Last $62.90 USD
Change Today -0.38 / -0.60%
Volume 5.2M
MDT On Other Exchanges
Symbol
Exchange
Mexico
Frankfurt
As of 8:04 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

710 Medtronic Parkway

Minneapolis, MN 55432

United States

Phone: 763-514-4000

Fax:

disease and is designed to allow physicians to deliver replacement valves through a catheter through the body’s cardiovascular system, eliminating the need to open the chest. The company’s TCVs include the CoreValve transfemoral aortic valve and Engager transapical aortic valves, as well as the Melody pulmonary valve. CoreValve, which is the only TCV system shown to be superior to open-heart surgery, has received the U.S. FDA approval for extreme risk patients and CE Mark approval. The company received the U.S. FDA approval for CoreValve in high risk patients in June 2014. Heart Valves: The company offers a line of surgical valve replacement and repair products for damaged or diseased heart valves. Its replacement products include both tissue and mechanical valves. The company’s replacement tissue valve product offerings include the Mosaic bioprosthetic stented, Freestyle stentless, Hancock II stented, Enable sutureless tissue (CE Mark countries), and 3f Biological tissue valves. Its mechanical valves include the Open Pivot valve. Its valve repair products include the Duran Flexible and CG Future Band, CG Composite Annuloplasty Systems, Profile 3D Annuloplasty Ring, Simulus Ring portfolio, and Tri-Ad Annuloplasty Ring. Arrested Heart Surgery: The company offers a line of blood-handling products that form this circulatory support system and maintain and monitor blood circulation and coagulation status, oxygen supply, and body temperature during arrested heart surgery. Its Affinity Fusion oxygenation system received both CE Mark and the U.S. FDA approval and is being launched worldwide. Beating Heart Surgery: To assist physicians performing beating heart surgery, the company offers positioning and stabilization technologies. These technologies include its Starfish 2 and Urchin heart positioners, which are designed to work in concert with its family of Octopus tissue stabilizers. Surgical Ablation: The company’s Cardioblate surgical ablation system, which includes the Cardioblate LP surgical ablation system, Cardioblate navigator tissue dissector, and Cardioblate Cryoflex system, allows cardiac surgeons to create ablation lines during cardiac surgery. Customers: The primary medical specialists who use the company’s Structural Heart products are cardiac surgeons and interventional cardiologists. Competition: The company’s primary competitors in the Structural Heart business are Edwards Lifesciences Corporation; St. Jude; Sorin; Maquet Medical Systems, which is part of the publicly-listed Swedish group of companies GETINGE AB; and Terumo Medical Corporation. Endovascular The Endovascular business includes a line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections), as well as peripheral vascular disease (PVD). The company’s products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The following are the principal products offered by its Endovascular business: Endovascular Stent Grafts: An endovascular stent graft is a minimally invasive device to treat aortic disease, such as an aortic aneurysm, which is a weakened and bulging area in the aorta, the major blood vessel that feeds blood to the body. The company’s products are designed to treat aortic aneurysms in either the abdomen (abdominal aortic aneurysm) or thoracic (TAA) regions of the aorta. Its product line includes a range of endovascular stent grafts and accessories, including the Endurant II abdominal stent graft system and the Valiant Captivia thoracic stent graft system. Peripheral Vascular Intervention (PVI): PVI includes various procedures to treat patients with PVD, a narrowing or blockage of vessels outside the heart, which impedes blood supply to the brain, kidneys, legs, and other vital organs. Similar to CAD, PVD is commonly treated with balloon angioplasty, which could be followed up with a peripheral stent. The company’s primary PVI products include percutaneous angioplasty balloons, including the IN.PACT family of drug-coated balloons, as well as sten

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $62.90 USD -0.38

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.04 USD +0.15
Allergan Inc/United States $170.06 USD -0.51
Astellas Pharma Inc ¥1,415 JPY +13.00
Baxter International Inc $76.65 USD -0.35
Covidien PLC $87.79 USD -1.31
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 20.8x
Price/Sales 3.7x
Price/Book 3.2x
Price/Cash Flow 18.4x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.